Condition (MeSH)
Non-Erosive Reflux Disease
ClinicalTrials.gov lists 46 trials for Non-Erosive Reflux Disease or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
46 of the 46 trials are tagged with Non-Erosive Reflux Disease itself; the rest are tagged with a narrower condition beneath it.
When did Non-Erosive Reflux Disease trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2015 | 4 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Non-Erosive Reflux Disease trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 12 |
| Phase 4 | 4 |
| Not applicable | 15 |
| Observational | 11 |
How many Non-Erosive Reflux Disease trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Completed | 26 |
| Terminated | 2 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Non-Erosive Reflux Disease trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 4 |
| Nycomed | 3 |
| Braintree Laboratories | 2 |
| Ahn-Gook Pharmaceuticals Co.,Ltd | 1 |
| Cellmedis | 1 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Non-Erosive Reflux Disease? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Magnesium Pantoprazole | 4 |
| BLI5100 | 4 |
| Omeprazole 20 mg | 3 |
| Sucralfate | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Nexium Pill | 5 |
| PPI | 2 |
| Acupuncture | 1 |
| EsoDuo Tab. 20/800mg | 1 |
| Control (placebo) group | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Non-Erosive Reflux Disease trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Bronchial carcinoma | 1 | 1 |
| Diarrhoea | 1 | 1 |
| Nervousness | 1 | 1 |
| Renal failure acute | 1 | 1 |
Which publications cover Non-Erosive Reflux Disease? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2024 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.